What should we do next?


Capabilities, shortcomings and recommendations, by development area

Basic research

What we have
What we don’t have
What we should do
  • Excellent scientists and a solid research ecosystem
  • Clear stimuli for tech transfer
  • Systematic approach to translate papers into solutions for society
  • Improve tech transfer incentives for researchers

Proof of Concept testing (“killer” experiments)

What we have
What we don’t have
What we should do
  • Specialized research capabilities and local expertise
  • Investor interest in intervening at this early stage
  • Market perspective
  • Serious commitment from academia to start clinical development
  • A connected and comprehensive drug-discovery platform
  • Public and private early-stage financing to prepare a preclinical regulatory package
  • Work together with scientists, pharma and investors to better define PoC experiments
  • Strengthen local drug-discovery platform
  • Provide specific public funding in this stage, such as by matching private investment funds

Preclinical and regulatory

What we have
What we don’t have
What we should do
  • A solid network of experts and providers
  • Knowledge from local pharmas
  • Market perspective
  • Serious commitment from academia to start clinical development
  • A connected and comprehensive drug-discovery platform
  • Public and private early-stage financing to prepare a preclinical regulatory package
  • Work together with scientists, pharma and investors to better define PoC experiments
  • Strengthen local drug-discovery platform
  • Provide specific public funding in this stage, such as by matching private investment funds

Clinical development

What we have
What we don’t have
What we should do
  • Professional expertise
  • A network of top-level hospitals
  • Specialized CROS
  • Integrated business development of Catalan clinical trials capabilities
  • Room for improvement with research ethics committees and local hospitals. Still too bureaucracy
  • Integrate more the CatSalut health system in streamlining clinical trials capabilities

Market Access

What we have
What we don’t have
What we should do
  • An integrated health system (CatSalut)
  • Innovation alignment from within the system
  • Low rate of incorporating innovations
  • The health system leading innovation by defining own needs
  • Improve innovative capabilities of the Catalan Health System
  • Implement innovative public procurement programs

Capabilities, shortcomings and recommendations, by key underlying enablers

Knowledge transfer

What we have
What we don’t have
What we should do
  • An excellent network of academic TTOs
  • TTOs are understaffed and not properly financed
  • Finance TTOs, mostly by channeling PoC funding through them

Management and professional talent

What we have
What we don’t have
What we should do
  • A network of professionals and providers coming from the local pharma industry
  • Dozens of C-level management teams with years of experience founding and scaling up start-ups
  • Serial entrepreneurs
  • Attract, retain, train and mentor C-level talent

Cluster strategy

What we have
What we don’t have
What we should do
  • Local mid-sized pharmas and some headquarters of big pharma
  • Connection between the three levels (start-ups, local mid-pharmas, large international pharmas)
  • Mid-tier innovative companies
  • Stimulate local pharmas to capture innovation from local companies
  • Encourage large pharma to scout for innovation in Catalonia
  • Promote partnerships between established pharma companies and innovative start-ups

Fiscal climate

What we have
What we don’t have
What we should do
  • Clumsy fiscal incentives for RDI
  • The culture of considering tax incentives as effective mechanisms to promote RDI
  • Establish an R&D tax-credit system
  • Develop enterprise investment schemes for business angels and investors

Finance

What we have
What we don’t have
What we should do
  • Entrepreneurial culture, business angels, local VCs and new-entrant international VCs
  • Organized and comprehensive public view of the relevance of private investment in promoting innovation in health
  • Attract capital through tax stimuli
  • Commit public funding through smart public-private instruments